Monthly Archives: April 2012

SXC HEALTH SOLUTIONS ANNOUNCES ACQUISITION OF MEDMETRICS HEALTH PARTNERS, INC. SXC Health Solutions Corp. (“SXC”) (NASDAQ: SXCI, TSX: SXC), announced today it has entered into a definitive agreement to acquire substantially all of the assets of MedMetrics Health Partners, Inc. … Continue reading →

BioScrip Pharmacy Accredited BioScrip Inc. (BIOS – Analyst Report), a health care-related company recently received accreditation for its specialty pharmacy and mail service pharmacy from Utilization Review Accreditation Commission (URAC), a Washington-based health care accrediting organization that establishes quality standards … Continue reading →

Endo, Biogen lead drug stocks north BOSTON (MarketWatch) — Endo Pharmaceuticals Holdings Inc. and Biogen Idec Inc. helped lead drug stocks north Monday, as the broader market also moved into positive territory. Shares of Endo (ENDP 41.34, +0.49, +1.20%) jumped … Continue reading →

SuperGen To Acquire Astex Pharmaceutical company SuperGen Inc, released a statement on Thursday stating the company has agreed to purchasing British based drug company Astex Therapeutics Ltd. SuperGen’s released partial terms of the deal stating that they will be acquiring … Continue reading →

Questions raised about industry influence on anti-depressant studies For more than two decades, researchers have been unable to settle an important question: Can anti-depressant medications stimulate the growth of breast and ovarian cancers? Some studies pointed to a link, but … Continue reading →

Merck Sees Inspiration in Eye Care Mergers and acquisitions continue in the pharma sector with Merck (MRK – Analyst Report) recently announcing its intention to acquire specialty pharma company Inspire Pharmaceuticals, Inc. (ISPH – Snapshot Report). The companies have entered … Continue reading →

New drugs from bugs Scientists from the Universities of Bristol and Birmingham have discovered how marine bacteria join together two antibiotics they make independently to produce a potent chemical that can kill drug-resistant strains of the MRSA superbug. Working with … Continue reading →

Rexahn Pharmaceuticals to Present at Needham & Company’s 10th Annual Healthcare Conference Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at Needham … Continue reading →